Skip to content
Screener

United Therapeutics UTHR Q2 2025 earnings

Reported July 30, 2025 · Before market open

Revenue$798.6MMiss by $3.3M
EPS$6.41Miss by $0.88
Revenue estimate$801.9M
EPS estimate$7.29

Next report

Nov 4, 2026 (in 2 months)
Revenue estimate$789.5M
EPS estimate$6.44

Financials

Q2 2025

Income statement

See full
Revenue$798.6M+11.7%
Gross profit$711.0M+11.6%
Operating income$364.5M+13.9%
Net income$309.5M+11.3%
EPS (diluted)$6.41+9.6%

Balance sheet

See full
Cash & equivalents$1.6B+17.5%
Total equity$7.2B+25.9%
Total assets$7.9B+17.6%

Cash flow

See full
Operating cash flow$191.7M-17.4%
CapEx$62.2M+37.9%
Free cash flow$129.5M-30.8%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$13.08B-12.6%
P/E10.5×-3.5×
P/S4.2×-1.5×

Profitability

See full
Gross margin89%+0.1pp
Operating margin47%-1.2pp
Net margin40.4%-0.5pp
FCF margin34.8%+1.2pp

Returns & leverage

See full
Return on equity19.3%0.0pp
Current ratio7.3×+2.9×

Segments

By product

See full
Tyvaso DPI$315.2M+22.0%
Nebulized Tyvaso$154.4M+10.4%
Remodulin$134.7M-8.6%
Orenitram$123.9M+15.7%
Unituxin$58.4M+13.0%

By geography

See full
U.S.$759.8M—

FAQ

When did United Therapeutics report Q2 2025 earnings?
United Therapeutics (UTHR) reported Q2 2025 earnings on July 30, 2025 before market open.
What were United Therapeutics's Q2 2025 revenue and EPS?
United Therapeutics reported revenue of $798.6M and eps of $6.41 for Q2 2025.
Did United Therapeutics beat estimates in Q2 2025?
Revenue missed the consensus estimate of $801.9M by $3.3M. EPS missed the consensus estimate of $7.29 by $0.88.
How did United Therapeutics's Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 11.7% from $714.9M a year earlier and eps grew 9.6% from $5.85.
Where can I find United Therapeutics's Q2 2025 SEC filings?
You can read the 8-K earnings release (0001628280-25-036543) and the 10-Q periodic report (0001628280-25-036541) directly on SEC EDGAR. The filing index links above go to sec.gov.